International Journal of Preventive Medicine (Int J Prev Med)2008-78024620130203700704ENDepartment of Celiac Disease, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Celiac Disease, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Celiac Disease, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Gastroenterology, Luton and Dunstable Hospital, NHS, Foundation Trust, Luton, Luton LU4 0DZ, United KingdomDepartment of Celiac Disease, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Gastroenterology, Alexandra Hospital, Worcestershire, B98 7UB, United KingdomDepartment of Celiac Disease, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran20130203<p><strong>Background: </strong>Celiac disease (CD) is an immune mediated condition that leads to small bowel atrophy that resolves with a gluten free diet (GFD). Extra-intestinal manifestations of CD include hypertransaminasemia. In this study, the effects of a GFD on hypertransaminasemia in patients with newly diagnosed CD were studied.</p> <p><strong>Methods: </strong>Ninety eight new diagnosed consecutive patients with CD 40 males and 58 females) with mean age of 32 &plusmn; 17.1 were studied. All patients with CD were treated with a GFD. Patients with hypertransaminasemia, at diagnosis, had a cirrhosis screen performed. Patients with a negative cirrhosis screen were reviewed, 6 months after the introduction of a GFD, and serum levels of liver transaminases were measured again.</p> <p><strong>Results: </strong>Nine patients had hypertransaminasemia. One patient was Hepatitis B surface antigen positive and was excluded from this study. The 8 remaining patients had no obvious cause for the hypertransaminasemia. Mean (&plusmn; SD) of baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 42.6 &plusmn; 16.5 IU/L (range: 16-66 IU/L) and 69.3 &plusmn; 9.3 IU/L (range: 52-81 IU/L). Six months after treatment with a GFD, mean AST and ALT levels decreased to 24.5 &plusmn; 5.1 IU/L (range: 18-31 IU/L) (<em>P</em>: 0.04) and 24.6 &plusmn; 6 IU/L (range: 17-32 IU/L) (<em>P</em>: 0.01), respectively. In 7 patients the hypertransaminasemia, at diagnosis had resolved.</p> <p><strong>Conclusions: </strong>This study provides further evidence that some patients with CD have a reversible hypertransaminasemia that resolves with a GFD.</p> <strong>Keywords: </strong>Celiac disease, gluten-free diet, hypertransaminasemia, liverhttp://ijpm.mui.ac.ir/index.php/ijpm/article/view/1053http://ijpm.mui.ac.ir/index.php/ijpm/article/download/1053/1072